Brief: Radiopharm Theranostics Got U.S. FDA IND Approval For Its Αvβ6 Integrin (Rad301) Technology
29/12/2022 23:40
Dec 30 (Reuters) - Radiopharm Theranostics Ltd RAD.AX :
* GOT U.S. FDA IND APPROVAL FOR ITS ΑVΒ6 INTEGRIN (RAD301)
TECHNOLOGY
Source text for Eikon: ID:nASX51ykFv
Further company coverage: RAD.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Radiopharm Theranostics
See all newsBrief: Radiopharm Theranostics Advances To Cohort 3 In 177Lu-RAD202 Phase 1 Dose Escalating Clinical Trial
Brief: Radiopharm Theranostics And Siemens Healthineers Sign Clinical Supply Agreement For Rad101 In The U.S.
Brief: Radiopharm Theranostics Says RAD And Siemens Sign Clinical Supply Agreement For Rad101
Brief: Radiopharm Theranostics Doses First Patient In Phase 1/2A Clinical Study Of Betabart
Brief: Radiopharm Theranostics Says Co Increases Ownership In Radiopharm Ventures To 87.5%